Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer.
International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Italy. Electronic address: aron.goldhirsch@ibcsg.org.
A
A
Goldhirsch
International Breast Cancer Study Group and University of Sydney, Sydney, Australia.
A S
AS
Coates
D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D057285:Precision Medicine / Q000379:methods*